fbpx
Connect with us

BUSINESS

Kush Bottles Inc (OTCMKTS:KSHB) Establishes a New Division to Supply Packaging Solutions To Veterinary and Pharmaceutical Industries

Published

on

Kush Bottles Inc (OTCMKTS:KSHB) has formed Koleto Packaging Solutions, a new division, to provide packaging solutions, which are FDA compliant, to the veterinary and pharmaceutical industries.

Estimates of Packaging Solutions for The Pharmaceutical Industries

The market for packaging solutions for the Pharmaceutical Industries worldwide is forecasted to reach US$158.8 Billion by the year 2025. Kush Bottles Inc will make use of the expertize it gained from the cannabis packaging business to provide the packaging solutions to the veterinary as well as pharmaceutical industries.

Executive Vice President, Edd Pratt will head the new unit Koleto Packaging Solutions to serve the packaging needs of both the industries in the US.

Nick Kovacevich, Chief Executive Officer of Kush Bottles Inc., said the company is a leader in offering cannabis focused packaging solutions. It is specialized in creating elegant products that comply with local and state regulations.

The company has an expertize to produce products for industry needs. While meeting the FDA regulations, it is able to produce child resistant containers that are ideal for veterinary and pharmaceutical needs.

Kush Bottles Inc also has an expertize to create the branded packaging to improve the appeal of products to the relevant segments.

Billions of dollars are pumped into the pharmaceutical research and innovative products are reaching the shelves every day. It can be challenging to improve their appeal and boost sales. Kush Bottles Inc. is well geared to design and create innovative packaging solutions for these products using the state of the art facilities.

Kush Bottles Inc Announces Closing of Offering of Common Stock Worth $36 million

Kush Bottles Inc has completed the sale of 7.5 million shares of the common stock under the restricted offering. The company also offered warrants to acquire 3.75 million shares at a combined price of $4.8 for each share.

The warrants, which have an exercise price of $5.28 for each share, can be exercised immediately. It will have a validity of 5 years from the date of the issue. The company will use the proceeds of $36 million for working capital, acquisitions, capital spending, product development, and other business opportunities.

BUSINESS

Real Brands Inc (OTCMKTS:RLBD) Signs An LOI To Purchase Proprietary CBD Formulas From Florida Based Integrative Medicine US

Published

on

Real Brands Inc (OTCMKTS:RLBD) has signed an LOI to buy proprietary CBD formulas of Integrative Medicine US. The formulas comprise ancient Chinese Medicine and Herbal Remedies that are blended CBD, nutrients, and endocannabinoid systems. Following the acquisition, Real Brands will use the formulas in its CBD Pharmacy brand. The company will use the new logo with a Chinese Symbol of healing.

CBD Pharmacy products

The initial product launch of CBD Pharmacy comprise salves, tinctures, balms, powders, and capsules developed to treat pain and promote relaxation, and boost immunity and energy.

Jerry Pearring, Chief Executive Officer of Real Brands, said medicinal herbs, CBD, and vitamins are blended using a proprietary formula to develop innovative medicine by Jonathan M. Fields, the founder of Integrative Medicine. The new products will help to keep the Real Brands in the driver’s seat to create a strong brand for CBD Pharmacy.

According to Pearring, CBD Pharmacy is expected to satisfy the growing consumer demand for hemp derived cannabidiol products. Consumers will also enjoy the benefits of eastern medical therapies.

Jonathan said the recent technological advances helped the company to develop superior medicinal products. Its features include Vegan, 100% Non-GMO, and tested in a third-party lab using cannabidiol. The company developed delivery mechanisms so that customers can get CBD and other ingredients in the right dosage to provide the desired effect for long-time.

Partners with Scot Piercy

Real Brands has partnered with Scot Piercy, a professional athlete, in April 2019. He will act as an ambassador for Real Brands Team and invested in the company last month. Pearring commenting the partnership said the company is excited to announce Scot as an ambassador. The investment shows the belief in the business model of the company and the long-term prospects. Pearring is pleased to welcome Scot on board Real Brands.

Piercy said he is proud to join the team of Real Brands. He studied about Real Brands and provides the support to grow hemp derived cannabidiol brands. Piercy further said it is looking forward to work with the company to introduce unique brands of Real Brands through e-commerce sites and retail channels.

Continue Reading

BUSINESS

Hexo Corp (NYSEAMERICAN:HEXO) Acquisition Of Newstrike Brands Finalized

Published

on

Acquisition now Finalized

Hexo Corp (NYSEAMERICAN:HEXO) has announced that it has completed the acquisition of all of Newstrike Brands’ issued and outstanding securities totaling 558,971, 064 marking the finalization of the acquisition process. The company has also received regulatory approval from relevant authorities including the high court further stamping the deal.

Reportedly, Newstrike Brands’ board of directors voted enthusiastically in favor of the acquisition that saw each of Newstrike’s stock exchanged for 0.06332 of Hexo’s share. Following the completion of the acquisition process, is expected to be delisted from TSX exchange platform as it will now operate under its new owner- Hexo.

Increased Production Space and Capacity

Popular voices in the industry believe that the $263 million acquisition sets Hexo among the industry’s elite. Among the several befits Hexo stands to gain from the acquisition includes additional production space estimated at 470,000 sqft. This is a significant addition to the company’s existing 1.3 million sqft.

With additional growing space comes increased production capacity. It is estimated that Hexo’s annual production capacity will surge from the current 110,000 kilos annually to a whopping 150,000 kilos annually which obviously translates to revenue influx.

Hexo’s CEO, Sebastien St-Louis said that “The combination of these two talented teams, both pioneers in the cannabis industry, will accelerate Hexo’s vision of creating the best cannabis technology company.” He adds that the Hexo is now commencing journey on the next phase of its progress.

The acquisition enhances the company’s solid position in the Canadian cannabis space and opening it up to countless possibilities abroad. The company already announced plans to set up operation in Greece as it seeks to seize the upcoming European market. Plans are also underway to set up operations in South America, the U.S (which is expected to open up fully by 2020), and more other locations.

The company already adjusted its 2020 revenue outlook to an optimistic $400 million. This projection factors in the company’s now bigger size in terms of production capacity and market access considering Hexo now assumes Newstrike’s distribution agreements with strategic partners across 8 Canadian provinces.

Continue Reading

BUSINESS

Synthetic MMJ Versus the Real Stuff

Published

on

CBD

When we use the term medical marijuana, we are referring to the entire unprocessed cannabis plant or its extracts for use as a pharmacological input in a treatment regime for individuals suffering from a variety of different health conditions. It may interest you to know that medical marijuana, at this point, only has explicit FDA approval as a safe and effective treatment for two conditions, both of which are severe and rare forms of epilepsy. Both of these conditions involve severe seizures and both of them represent conditions that no other pharmaceutical solution has been able to treat.

The established pharmaceutical version of medical marijuana that is used to treat these conditions is known as Epidiolex. This medication contains a pure form of CBD, and the FDA gave this approval in June 2018. Note it is also important to understand that the FDA has approved medications containing a synthetic version of THC known as Marinol and Cesamet. These drugs are used to treat nausea in people who are undergoing treatments for cancer and HIV. Interestingly, the FDA has not approved any marijuana-based drugs for the treatment of chronic or acute pain.

Synthetic versions of marijuana are often referred to as “Spice” or “K2”. According to the National Institute on drug abuse, synthetic marijuana is not considered marijuana. It is also not considered safe and is not recommended for any purpose. The important point to understand here is that synthetic marijuana attempts through chemical means to reproduce the essential function of marijuana as it interacts with human physiology. This runs up against what is known as the entourage effect – the idea that all of the elements of the cannabis plant work together in ways that supersede the impacts of just CBD or THC working alone.

Seen from this perspective, synthetic marijuana may not be nearly as effective and may have additional side effects that are difficult to account for.

Continue Reading
Advertisement
Advertisement
Advertisement






Trending Stories